This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharmaceuticals Products Inc.. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Eric Bruckert: Innovator in Apolipoprotein Research
Introduction
Eric Bruckert is a notable inventor based in Meudon, France. He has made significant contributions to the field of biotechnology, particularly in the study of apolipoproteins. His work has implications for therapeutic applications, especially in gene therapy.
Latest Patents
Eric Bruckert holds a patent for "Variants of apolipoprotein A-I." This invention relates to variants of the human apolipoprotein A-I that include a cysteine at position 151. The patent also covers the corresponding nucleic acids and vectors containing them. Furthermore, it discusses pharmaceutical compositions that incorporate these elements and their potential use in gene therapy.
Career Highlights
Bruckert is associated with Aventis Pharmaceuticals Products Inc., where he has been involved in groundbreaking research. His work has contributed to advancements in the understanding of lipid metabolism and cardiovascular health.
Collaborations
Throughout his career, Eric has collaborated with esteemed colleagues such as Patrick Benoit and Patrice Denefle. These partnerships have fostered innovation and have been instrumental in the development of his research.
Conclusion
Eric Bruckert's contributions to the field of biotechnology, particularly through his patent on apolipoprotein A-I variants, highlight his role as an innovator. His work continues to influence the landscape of gene therapy and pharmaceutical development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile